Sequent Scientific Limited reported earnings results for the second quarter and six months ended September 30, 2025. For the second quarter, the company reported sales was INR 4,239.9 million compared to INR 3,686.5 million a year ago. Revenue was INR 4,261.4 million compared to INR 3,731.6 million a year ago. Net income was INR 147.4 million compared to INR 26.1 million a year ago. Basic earnings per share from continuing operations was INR 0.59 compared to INR 0.11 a year ago. Diluted earnings per share from continuing operations was INR 0.58 compared to INR 0.1 a year ago.
For the six months, sales was INR 8,654.1 million compared to INR 7,588.6 million a year ago. Revenue was INR 8,714.3 million compared to INR 7,660.5 million a year ago. Net income was INR 290.5 million compared to INR 91.2 million a year ago. Basic earnings per share from continuing operations was INR 1.16 compared to INR 0.37 a year ago. Diluted earnings per share from continuing operations was INR 1.14 compared to INR 0.36 a year ago.
SeQuent Scientific Limited is an India-based animal health company. The Company provides a wide range of animal health products, including finished dose formulations, active pharmaceutical ingredients (APIs), as well as analytical services. The Company operates through the pharmaceuticals segment. The Company is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It is specialized in analytical and bio analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It provides analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer developed methods or in-house method development. The Company’s subsidiaries include Alivira Animal Health Limited and SeQuent Research Limited.
